Kura Oncology Inc (NAS:KURA)
$ 8.86 -0.08 (-0.89%) Market Cap: 688.99 Mil Enterprise Value: 250.32 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 29/100

Kura Oncology Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript

Jun 02, 2022 / 07:30PM GMT
Release Date Price: $13.49 (-0.66%)
Phil Nadeau
Cowen and Company, LLC - Analyst

Good afternoon and welcome once again to Cowen's Third Annual Oncology Innovation Summit. I'm Phil Nadeau, one of Cowen's biotech analysts. It's my pleasure to next moderate a fireside chat with Troy Wilson, the President and CEO of Kura Oncology.

Questions & Answers

Phil Nadeau
Cowen and Company, LLC - Analyst

Troy, there's a lot of focus on ziftomenib and the upcoming data. Could you maybe begin by providing a brief review of the efficacy and safety data from ziftomenib's KOMET-001 trial that have already been presented?

Troy Wilson
Kura Oncology, Inc. - President & CEO

Sure, Phil. And thank you to you and Cowen for the opportunity to participate in the summit. It's our pleasure. So ziftomenib has been in the Phase 1 and is currently in a Phase 1b -- excuse me -- Phase 1a/Phase 1b. The takeaways from the Phase 1a were good safety and tolerability, evidence of activity in the genetically selected populations. But because we were in an unselected

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot